Last reviewed · How we verify

NCT05132283

Urologic Lymphadenectomy in AMIGO

Status unknown NA Last updated 24 October 2023
What this trial tests

NA trial testing 3D Slicer in Urologic Cancer in 20 participants. Status unknown.

Timeline
1 April 2022
Primary endpoint
26 August 2025
26 December 2025

Quick facts

Lead sponsorDana-Farber Cancer Institute
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment20
Start date1 April 2022
Primary completion26 August 2025
Estimated completion26 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Urologic Cancer or Lymph Node Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study involves the use of two navigation systems, the 3D Slicer-based navigation system, and the Siemens Monaco systems, to simplify the complexity of image-guided lymphadenectomy procedures (surgery to remove one or more lymph nodes) in patients with urological cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Urologic Cancer

Currently open trials in the same condition.

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05132283.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing